Combination of asciminib, a novel and specific BCR-ABL1 inhibitor, plus imatinib in previously treated chronic myeloid leukemia (CML) patients: Phase 1 study results Meeting Abstract


Authors: Talpaz, M.; Cortes, J.; Lang, F.; Kim, D. W.; Réa, D.; Mauro, M. J.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; Goh, Y. T.; Le Coutre, P. D.; Sondhi, M.; Mishra, K.; Hourcade-Potelleret, F.; Vanasse, G.; Aimone, P.; Hughes, T. P.
Abstract Title: Combination of asciminib, a novel and specific BCR-ABL1 inhibitor, plus imatinib in previously treated chronic myeloid leukemia (CML) patients: Phase 1 study results
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: clinical trial; imatinib; cml; tyrosine kinase inhibitor; chronic myelogenous leukemia; asciminib
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S287
End Page: S288
Language: English
ACCESSION: WOS:000483480700268
DOI: 10.1016/j.clml.2019.07.231
PROVIDER: wos
Notes: Meeting Abstract: CML-041 -- Source: Wos
Altmetric Score
MSK Authors
  1. Michael John Mauro
    134 Mauro